The Patient-Reported Outcomes Project of HCV-TARGET



Status:Completed
Conditions:Gastrointestinal, Hepatitis, Hepatitis
Therapuetic Areas:Gastroenterology, Immunology / Infectious Diseases
Healthy:No
Age Range:21 - Any
Updated:10/27/2018
Start Date:November 2015
End Date:July 2018

Use our guide to learn which trials are right for you!

The Patient-Reported Outcomes Project of HCV-TARGET (PROP UP)

The PROP UP research study is funded by The Patient Centered Outcomes Research Institute
(PCORI). PROP UP is a multi-centered prospective observational study that will evaluate
all-oral treatment regimens for HCV regarding several patient-reported outcomes (PROs) such
as HCV-associated symptoms, treatment side effects, medication adherence, out of pocket
costs, comorbid conditions, and long-term benefits of cure and harms of treatment to compare
PROs of different treatment regimens, treatment durations, and patient subgroups.
Participants will be recruited from 9 U.S. liver centers. Approximately 1920 patients with
HCV infection who are prescribed a regimen containing Harvoni®, Viekera Pak®, Zepatier®,
DAC/SOF or SOF/VEL for chronic HCV will be recruited and approximately 1600 patients who are
approved and begin HCV treatment will be enrolled in the longitudinal study. PRO surveys will
be evaluated before, during and after HCV treatment.

PROP UP is a collaborative effort between behavioral and biomedical researchers, a patient
engagement group and a patient advocacy organization.

Newer, more effective all-oral regimens for hepatitis C viral (HCV) infection are available.
However the available data from industry-sponsored trials do not provide all the information
that patients need, nor do these data represent the broad spectrum of patients treated in
real-world practice. Trials also exclude disadvantaged subgroups, focus on short-term
efficacy and clinician-rated adverse events, rarely obtain the patient's perspective, and do
not investigate longer-term harms of treatment or benefits of viral cure. Given these
informational gaps, patient-centered outcomes research (PCOR) on treatment harms and benefits
that matter most to patients, is needed.

PROP UP is funded by The Patient Centered Outcomes Research Institute (PCORI). PROP UP is a
multi-centered prospective observational study that will evaluate 5 newly approved DAA
treatment regimens for HCV regarding several patient-reported outcomes (PROs) such as
HCV-associated symptoms, treatment side effects, medication adherence, out of pocket costs,
comorbid conditions, and long-term benefits of cure and harms of treatment to compare PROs of
different treatment regimens, treatment durations, and patient subgroups.

PROP UP is a collaborative effort between researchers, a patient engagement group, and a
patient advocacy organization. Nine U.S. liver centers will collaborate on PROP UP.
Approximately 1920 patients with HCV infection who are prescribed a regimen containing
Harvoni®, Viekera Pak®, Zepatier®, DAC/SOF or SOF/VEL for chronic HCV will be consented and
will complete baseline PRO surveys. Approximately 1600 patients who are approved and begin
HCV treatment will be enrolled in the longitudinal study. Participants will complete several
PRO surveys at 5 assessment periods during the study: baseline, treatment week 4, end of
treatment, 3 months post-treatment, and 12 months post-treatment. PRO survey data will be
collected via 3 options: patient home-based computers, tablet, smartphone; phone-administered
surveys with a centralized call enter; or at regular clinic visits.

Analysis of PROs collected longitudinally before, during and after treatment for HCV will
allow the investigators to answer a variety of questions important to patients and
clinicians. Specifically, the investigators will evaluate: (a) prevalence of pre-existing
baseline symptoms associated with HCV; (b) the development of new onset treatment side
effects and exacerbation of pre-existing symptoms during HCV treatment; (c) medication
adherence and out of pocket costs associated with treatment; (d) changes in HCV-associated
symptoms and functional status in patients who are cured; (e) long-term patient-reported
harms associated with treatments and long-term benefits associated with viral cure.

Inclusion Criteria:

- Diagnosed with HCV genotype 1-6

- English-speaking

- Age 21 or older

- Medically cleared and being prescribed one of the following DAA regimens:

- sofosbuvir/ledipasvir (Harvoni®) with or without ribavirin

- ombitasvir/paritaprevir/ritonavir with dasabuvir (Viekera Pak®), VPK) with or
without ribavirin

- elbasvir/grazoprevir (Zepatier®) with or without ribavirin

- daclatasvir/sofosbuvir, with or without ribavirin (DAC/SOF)

- sofosbuvir/velpatasvir (SOF/VEL)

Exclusion Criteria:

- Inability to provide written informed consent

- Currently participating in a pharmaceutical-sponsored drug trial of hepatitis C
treatment

- Major cognitive or mental impairment

- Unable to read or speak English

- Unwilling or unable to complete survey questionnaires
We found this trial at
11
sites
New Haven, Connecticut 6520
(203) 432-4771
Principal Investigator: Joseph Lim, MD
Phone: 203-785-2204
Yale University Yale's roots can be traced back to the 1640s, when colonial clergymen led...
?
mi
from
New Haven, CT
Click here to add this to my saved trials
Chapel Hill, North Carolina 27599
(919) 962-2211
Principal Investigator: Donna M. Evon, PhD
Phone: 919-966-4847
University of North Carolina at Chapel Hill Carolina’s vibrant people and programs attest to the...
?
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Gainesville, Florida 32610
(352) 392-3261
Principal Investigator: David Nelson, MD
Phone: 352-273-9464
University of Florida The University of Florida (UF) is a major, public, comprehensive, land-grant, research...
?
mi
from
Gainesville, FL
Click here to add this to my saved trials
500 S State St
Ann Arbor, Michigan 48109
(734) 764-1817
Principal Investigator: Anna Lok, MD
Phone: 734-647-0236
University of Michigan The University of Michigan was founded in 1817 as one of the...
?
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Asheville, North Carolina 28801
?
mi
from
Asheville, NC
Click here to add this to my saved trials
Chicago, Illinois 60612
Principal Investigator: Nancy Reau, MD
Phone: 312-942-1372
?
mi
from
Chicago, IL
Click here to add this to my saved trials
Davis, California 95616
Phone: 916-703-4372
?
mi
from
Davis, CA
Click here to add this to my saved trials
3451 Walnut St
Philadelphia, Pennsylvania 19104
1 (215) 898-5000
Principal Investigator: Rajender Reddy, MD
Phone: 215-349-8549
Univ of Pennsylvania Penn has a long and proud tradition of intellectual rigor and pursuit...
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Richmond, Virginia 23298
(804) 828-0100
Principal Investigator: Richard Sterling, MD
Phone: 804-828-9154
Virginia Commonwealth University Since our founding as a medical school in 1838, Virginia Commonwealth University...
?
mi
from
Richmond, VA
Click here to add this to my saved trials
Saint Louis, Missouri 63110
?
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Wilmington, North Carolina 28403
?
mi
from
Wilmington, NC
Click here to add this to my saved trials